Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Invesco Ltd.

Invesco Ltd. boosted its stake in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 54.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,749 shares of the company’s stock after buying an additional 13,620 shares during the quarter. Invesco Ltd.’s holdings in Sutro Biopharma were worth $71,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new stake in Sutro Biopharma in the 4th quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Sutro Biopharma during the fourth quarter worth $32,000. Vontobel Holding Ltd. grew its stake in shares of Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $46,000 after buying an additional 10,000 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Sutro Biopharma by 16.6% in the 4th quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock valued at $74,000 after buying an additional 5,770 shares during the period. Finally, Virtu Financial LLC acquired a new position in Sutro Biopharma during the 3rd quarter worth about $77,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on STRO shares. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Piper Sandler set a $2.00 price objective on shares of Sutro Biopharma in a report on Friday, March 14th. Bank of America lowered shares of Sutro Biopharma from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Wedbush cut shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $8.00 to $2.00 in a research report on Friday, March 14th. Finally, Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Sutro Biopharma has a consensus rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Trading Down 4.5 %

Shares of STRO opened at $1.05 on Tuesday. The firm has a market capitalization of $88.58 million, a price-to-earnings ratio of -0.65 and a beta of 1.77. The firm’s fifty day simple moving average is $0.90 and its 200-day simple moving average is $1.90. Sutro Biopharma, Inc. has a twelve month low of $0.52 and a twelve month high of $5.17.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). The business had revenue of $14.00 million during the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same quarter in the prior year, the business earned ($1.78) earnings per share. On average, analysts predict that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.